Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies
The Journal of Clinical Pharmacology · 2025
DOI: 10.1002/jcph.70059 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2025. Verfasst von Zhengzhe Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Program in Pharmacology and Drug Development, Tufts University School of Medicine, Boston, MA, USA. Hauptthemen laut MEDLINE: Ketoconazole, Cytochrome P-450 CYP3A Inhibitors, Antidepressive Agents, Piperazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NIDDK NIH HHS, DJG is supported in part by Grant.
Abstract (Originalsprache)
Gepirone, an antidepressant drug, is biotransformed into two principal metabolites [1‐(2‐pyrimidinyl)‐piperazine (1‐PP) and 3′‐OH‐gepirone] primarily by CYP3A enzymes. Metabolism of gepirone in the presence of ketoconazole, a potent inhibitor of human CYP3A activity, was studied in vitro in human liver microsomes. The clinical pharmacokinetic interaction of ketoconazole (as a maximal chemical inhibitor of CYP3A isoforms) with single doses of gepirone was evaluated in a Phase 1 study in human volunteers (N = 24). In vitro coincubation of gepirone with increasing concentrations of ketoconazole produced extensive inhibition of 1‐PP and 3′‐OH‐gepirone formation, with IC 50 values in the range of 0.026 µM to 0.162 µM. These inhibitory values are substantially lower than clinically encountered systemic concentrations of ketoconazole, thereby predicting extensive in vivo increases in gepirone exposure when coadministered with ketoconazole. In the clinical pharmacokinetic study, ketoconazole produced large increases in gepirone exposure by factors of 5.92‐ to 7.80‐fold. Appearance of 1‐PP in the systemic circulation decreased by factors of 0.56 to 0.97, while appearance of 3′‐OH‐gepirone increased by 1.70‐ to 2.43‐fold. The clinical findings are consistent with the in vitro results, and underlie the labeling recommendation that gepirone not be coadministered with “strong” CYP3A inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Pharmacology and Drug Development, Tufts University School of Medicine, Boston, MA, USA.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- University of Florida College of Pharmacy, Gainesville, FL, USA.
- Center for Pharmacogenomics and Precision Medicine, University of Florida, Gainesville, FL, USA.
- Clinical and Translational Sciences Institute, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, USA.
Förderung
- NIDDK NIH HHS
- DJG is supported in part by Grant
Zitieren
APA
Yang, Z., Hossain, M. A., Zhang, Q., Liu, L., Singleton, C. A., Markowitz, J. S., & Greenblatt, D. J. (2025). Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70059
Vancouver
Yang Z, Hossain MA, Zhang Q, Liu L, Singleton CA, Markowitz JS, et al. Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies. The Journal of Clinical Pharmacology. 2025. doi:10.1002/jcph.70059
BibTeX
@article{Yang2025,
author = {Yang, Zhengzhe and Hossain, Md Amin and Zhang, Qingchen and Liu, Longyue and Singleton, Christopher A and Markowitz, John S and Greenblatt, David J},
title = {Ketoconazole Inhibition of Gepirone Biotransformation and Clearance: In Vitro and Clinical Studies},
journal = {The Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/jcph.70059}
}
EUVIMED